Introduction
Ocular myasthenia gravis falls under the category of myasthenia gravis. It is a neuromuscular disorder that transmits signal transmission from nerves to muscles. In the ocular myasthenia gravis, the muscles that control eye movements are affected. The condition can lead to drooping eyelids, double vision, and difficulty in focusing. The condition affects people aged between 20 to 40. The management involves a combination of pharmacological therapies such as immunomodulatory agents and acetylcholinesterase inhibitors. The non-pharmacological approaches include electrodiagnostic testing and thymectomy. The treatment can help the patient in relieving the symptoms. In recent years, there have been several recent advances in the management of ocular myasthenia gravis which include immunomodulatory therapies.
What Is Ocular Myasthenia Gravis?
The autoimmune disorder affects the nerves and muscles. The muscles which control eye movement are most commonly harmed. The common symptoms are double vision and drooping eyelids.
What Are the Causes of Ocular Myasthenia Gravis?
The exact cause of ocular myasthenia gravis is not known. The condition is considered an autoimmune disorder. The body attacks its own healthy cells. The antibodies produced by the immune system target a protein called the acetylcholine receptor. The receptor is present at the junction where the nerves connect to the muscles. This receptor plays an important role in transmitting signals from the nerves to the muscles. When the antibodies attack these receptors can lead to fatigue and muscle weakness.
The other factors that can contribute to the development of the condition are genetics, environmental factors, and infections. Environmental factors such as toxins and viruses can trigger the autoimmune response in susceptible people. Certain medications such as muscle relaxants and antibiotics may worsen the symptoms.
What Are the Signs and Symptoms of Ocular Myasthenia Gravis?
The symptoms may come and go. Some factors like stress, fatigue, and illness may worsen the condition. The condition may affect other muscles and may lead to generalized myasthenia gravis. The signs and symptoms are as follows:
-
Drooping of eyelids (ptosis).
-
Blurred vision.
-
Double vision (diplopia).
-
Difficulty in moving the eyes in all directions.
-
Eye spasm or twitching (nystagmus).
-
Fatigue or eye muscle weakness.
How Can Ocular Myasthenia Gravis Be Diagnosed?
The diagnosis typically involves a medical history, physical examination, and specialized test. The diagnostic measures are as follows:
-
Medical History: The healthcare provider may ask about the patient's symptoms and other medical conditions. The doctor may also ask the patient that whether they suffered from the condition in the past.
-
Physical Examination: The healthcare provider may physically examine the muscles that control eye movements.
-
Specialized Tests: The healthcare provider may prescribe blood tests to detect specific antibodies associated with the condition. Electromyography testing can be conducted to evaluate the functionality of the muscles and nerves responsible for controlling eye movement.
How Can Ocular Myasthenia Gravis Be Treated?
The treatment is a multidisciplinary approach including a team of ophthalmologists, neurologists, and immunologists. It reduces the severity and frequency of symptoms. The treatment measures are as follows:
- Medications: Medications can improve the communication between muscles and nerves, such as anticholinesterase inhibitors. It is the first line of therapy drugs for ocular myasthenia gravis. The medications increase the availability of acetylcholine. Acetylcholine is a chemical messenger that transmits signals between muscles and nerves. Immunosuppressive drugs can be employed to diminish inflammation and inhibit the immune system.
-
Thymectomy: The procedure involves the removal of the thymus gland. It is recommended in cases where the patient has an abnormal or enlarged thymus gland. The procedure is beneficial in reducing the symptoms.
-
Symptomatic Treatment: In addition to medications, other treatment strategies may be used to manage the symptoms. For example, eye patches and prism glasses may be used to improve eye misalignment and double vision. Surgery may be advised to improve eye drooling and other symptoms.
-
Regular Follow-Up: Regular follow-up is essential for the effective management of the condition. Depending on the patient's response to therapy the treatment plan may be adjusted.
What Are the Recent Advances in the Management of Ocular Myasthenia Gravis?
Recent advances have been focused on improving the safety and effectiveness of the existing treatment options. The recent advances are as follows:
-
Immunomodulatory Therapies: The role of immunomodulatory therapies including monoclonal antibodies is to improve the symptoms in patients with ocular myasthenia gravis. This therapy reduces inflammation. The medications include Eculizumab blocks the immune system called the terminal complement cascade. These bind to the antibodies and damage the junction between muscle and nerve. Rituximab and Belimumab are the other monoclonal antibodies that suppress antibody production.
-
Novel Acetylcholinesterase Inhibitors: These improve neuromuscular transmission. These drugs prevent the breakdown of acetylcholine. The medication includes Pyridostigmine bromide is available in the form of tablets and liquid. These drugs can cause diarrhea and stomach cramps.
-
Telemedicine: Remote monitoring and telemedicine technologies are beneficial for patients who live in areas or have difficulty traveling to take appointments.
-
Plasmapheresis: It is a plasma exchange procedure that removes the antibodies from the blood. The procedure is prescribed for patients with severe ocular myasthenia gravis symptoms and who do not respond to other treatments. With plasma exchange, a person gets stronger in several days. It involves removing a large volume of blood and lowering blood pressure.
-
Supplemental Therapies: It includes eating a balanced and healthy diet, exercising regularly, managing stress, improving mood, and dealing with an illness that may improve individual health.
Conclusion
Ocular myasthenia gravis is a condition that affects the neuromuscular junction leading to fatigue and weakness of the nerves and muscles that controls eye movement. Several recent advances improve the outcomes of the patient. The recent advances involve immunomodulatory drugs, such as corticosteroids and immunosuppressants. The drugs suppress the immune system that attacks the junction of nerves and muscles. It reduces the symptoms and further damage. In addition, monoclonal antibodies are used in the management of the symptoms. Another procedure includes thymectomy involves the removal of the thymus gland which improves the outcome in some patients. The supplemental therapies include yoga, acupuncture, dietary supplements, and managing stress may be helpful in managing the symptoms.
